Prashant Kapoor, MD, FACP
Prashant Kapoor, MD, FACP, is a Consultant and an Associate Professor of Medicine at Mayo Clinic, Rochester, Minnesota. He is also the Chair of the Mayo Clinic Waldenström Macroglobulinemia Working Group. He was awarded the Kurtz Plasma cell Disorder Research Fellowship at Mayo Clinic in 2008 following which he commenced his clinical fellowship training in Hematology and Oncology at Mayo Clinic. Upon completion of his training in 2012, he was invited to serve as faculty in the Division of Hematology, Mayo Clinic.
He is a recipient of the American Society of Clinical Oncology (ASCO) Merit Award, Department of Medicine (DOM) Career Development Award, Research Innovation Award, Transplant Center Scholar Award, and the Department of Medicine Faculty Scholar Award.
His research is focused in evaluating novel agents in plasma cell disorders. He is a principal investigator of several investigator-initiated and industry-sponsored clinical trials. He has served on the Mayo Clinic Institutional Review Board and is currently a member of the Mayo Cancer Center Data Safety Monitoring Committee.
He is a passionate educator and has participated and organized educational seminars for patients and their families. He has presented his work at the national and international forums. He has served on the Editorial Board of the American Society of Hematology (ASH) Daily News and is the Myeloma Section Editor of Current Hematologic Malignancy Reports and Co-Site Editor for Myeloma Section of JNCCN 360. He has over 350 publications in prestigious journals, including The Lancet, JAMA Oncology, Journal of Clinical Oncology, The Lancet Oncology, Blood, The Lancet Haematology and Leukemia.
He is a fellow at the American College of Physicians, and an active member of the International Myeloma Working Group, American Society of Hematology, American Society of Clinical Oncology and the International Myeloma Society.
Financial relationships
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:AmgenDate added:08/10/2023Date updated:05/20/2024
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:RegeneronDate added:08/10/2023Date updated:05/20/2024
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:Bristol Myers Squibb,Date added:08/10/2023Date updated:05/20/2024
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:Loxo PharmaceuticalsDate added:08/10/2023Date updated:05/20/2024
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:IchnosDate added:08/10/2023Date updated:05/20/2024
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:KaryopharmDate added:08/10/2023Date updated:05/20/2024
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:SanofiDate added:08/10/2023Date updated:05/20/2024
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:AbbVieDate added:08/10/2023Date updated:05/20/2024
-
Attribution:OtherType of financial relationship:Grant Or ContractIneligible company:GlaxoSmithKlineDate added:08/10/2023Date updated:05/20/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BeiGeneDate added:08/10/2023Date updated:05/20/2024